-
公开(公告)号：US09518087B2
公开(公告)日：2016-12-13
申请号：US13206034
申请日：2011-08-09
IPC分类号： A61K39/00 , A61K35/18 , C07K7/08 , B82Y5/00 , C07K16/18 , C07K16/28 , C07K16/30 , C07K14/47 , A61K38/00
CPC分类号： C07K16/28 , A61K38/00 , A61K39/0008 , A61K39/001 , A61K47/6849 , A61K2039/505 , A61K2039/6031 , A61K2039/6056 , B82Y5/00 , C07K7/08 , C07K14/4701 , C07K14/77 , C07K16/18 , C07K16/30 , C07K2317/34 , C07K2317/622 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/33 , C07K2319/41 , C07K2319/43 , C07K2319/74 , A61K2039/57 , A61K2039/577
摘要： Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
摘要翻译： 描述了特异性结合红细胞的肽。 这些作为肽配体提供，其具有与红细胞特异性结合的序列，或作为提供特异性结合的抗体或其片段。 肽可以制备成具有治疗剂，耐受抗原或靶向肽的分子融合物。 可以通过使用融合物和在需要耐受性的物质上选择抗原来产生免疫耐受性。 与靶向肽的融合将融合物引导到靶，例如肿瘤，其中红细胞结合配体通过向目标募集红细胞而减少或完全消除血液流向肿瘤的血液。
-
公开(公告)号：US20140154271A1
公开(公告)日：2014-06-05
申请号：US14119263
申请日：2012-05-31
申请人： Maria Deato , Hong Yang , Daniel David Kaplan
发明人： Maria Deato , Hong Yang , Daniel David Kaplan
CPC分类号： C07K14/4701 , C07K14/47 , C07K2319/30
摘要： Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
摘要翻译： 提供了治疗患有葡萄糖代谢障碍的个体的方法及其组合物。
-
公开(公告)号：US20120039989A1
公开(公告)日：2012-02-16
申请号：US13206034
申请日：2011-08-09
IPC分类号： A61K9/127 , C07K7/08 , C07K14/00 , C07K19/00 , C12N9/96 , A61K39/44 , A61K38/02 , A61K38/48 , C07K2/00 , A61P35/00 , A61P37/04 , C07K7/06 , A61K39/385 , B82Y5/00
CPC分类号： C07K16/28 , A61K38/00 , A61K39/0008 , A61K39/001 , A61K47/6849 , A61K2039/505 , A61K2039/6031 , A61K2039/6056 , B82Y5/00 , C07K7/08 , C07K14/4701 , C07K14/77 , C07K16/18 , C07K16/30 , C07K2317/34 , C07K2317/622 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/33 , C07K2319/41 , C07K2319/43 , C07K2319/74 , A61K2039/57 , A61K2039/577
摘要： Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
摘要翻译： 描述了特异性结合红细胞的肽。 这些作为肽配体提供，其具有与红细胞特异性结合的序列，或作为提供特异性结合的抗体或其片段。 肽可以制备成具有治疗剂，耐受抗原或靶向肽的分子融合物。 可以通过使用融合物和在需要耐受性的物质上选择抗原来产生免疫耐受性。 与靶向肽的融合将融合物引导到靶，例如肿瘤，其中红细胞结合配体通过向目标募集红细胞而减少或完全消除血液流向肿瘤的血液。
-
公开(公告)号：US20040029197A1
公开(公告)日：2004-02-12
申请号：US10363791
申请日：2003-03-07
IPC分类号： G01N033/574 , C07H021/04 , C12P021/02 , C12N005/06 , C07K014/47
CPC分类号： C07K14/82 , A61K39/00 , C07K14/4701 , C07K14/4748 , G01N33/505 , G01N2500/00
摘要： The present invention provides a cancer/testis antigen which is applicable to diagnosis and immunotherapy for cancer, that is to say, to provide a cancer/testis antigen which is not expressed in normal tissues other than the testis, which is expressed in various cancers over a broad range and which induces immune response in a host, and to provide a caner/testis gene encoding the cancer/testis antigen, etc. By using the yeast Two-hybrid System, the present inventors screened a protein which specifically binds to GCF, a previously reported transcription factor, cloned a gene of a protein specifically binding to the GCF, confirmed that the D40 protein as a resulting gene product is a cancer/testis antigen which is expressed substantially only in the testis in normal human tissues whereas in cancers it is expressed in human primary cancers over a broad range derived from various tissues and cells, and found that the D40 shows high affinity with HLA and has a plurality of sequences comprising 9 or 10 amino acid residues and binding to HLA.
摘要翻译： 本发明提供了癌症/睾丸抗原，其可应用于癌症的诊断和免疫治疗，也就是说，提供在睾丸以外的正常组织中不表达的癌/睾丸抗原，其在各种癌症中表达 广泛范围，并且在宿主中诱导免疫应答，并提供编码癌/睾丸抗原的睾丸/睾丸基因等。通过使用酵母双杂交系统，本发明人筛选了与GCF特异性结合的蛋白质， 克隆了与GCF特异性结合的蛋白质的基因的先前报道的转录因子证实，作为所得基因产物的D40蛋白是癌基因/睾丸抗原，其仅在正常人组织中仅在睾丸中表达，而在癌症中 在源自各种组织和细胞的广泛范围内在人类原代癌症中表达，并且发现D40与HLA具有高亲和力，并且具有多个序列，其包含 9或10个氨基酸残基并与HLA结合。
-
公开(公告)号：US06472515B1
公开(公告)日：2002-10-29
申请号：US09645629
申请日：2000-08-24
IPC分类号： C07H2104
CPC分类号： C12N15/11 , C07K14/4701 , C07K14/4702 , C07K2319/00 , C12N15/85 , C12N2830/002
摘要： The present invention is directed to a novel Afx response element comprising the nucleotide sequence AACATGTT, said nucleotide sequence having a DNA binding site for the human fork head transkription factor Afx. The invention also relates to the use of the Afx response element in the screening for genes as diabetes drug targets and in the bioinformatic analysis of the human genome, said genes in turn being useful in other screening methods for compounds modifying the insulin receptor signaling pathway. A further aspect of the invention is a vector construct comprising the novel nucleotide sequence, a host cell transformed with said vector construct as well as the fusion protein expressed by said host cell.
摘要翻译： 本发明涉及包含核苷酸序列AACATGTT一种新颖AFX响应元件，所述具有用于人类叉形头transkription因子AFX一个DNA结合位点的核苷酸序列。 本发明还涉及到在筛选基因作为糖尿病药物靶标和在人类基因组的生物信息学分析使用AFX应答元件，所述基因又是在其他筛选方法用于修改所述胰岛素受体信号转导通路的化合物是有用的。 本发明的进一步的方面是载体构建体，其包括新颖的核苷酸序列，在转化的宿主细胞，所述载体构建体以及由所表达的融合蛋白，所述宿主细胞。
-
-
-
-
搜索结果
25 条记录 (耗时 0.024 秒)
